JP2004163388A5 - - Google Patents

Download PDF

Info

Publication number
JP2004163388A5
JP2004163388A5 JP2003095679A JP2003095679A JP2004163388A5 JP 2004163388 A5 JP2004163388 A5 JP 2004163388A5 JP 2003095679 A JP2003095679 A JP 2003095679A JP 2003095679 A JP2003095679 A JP 2003095679A JP 2004163388 A5 JP2004163388 A5 JP 2004163388A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003095679A
Other languages
Japanese (ja)
Other versions
JP2004163388A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2004163388A publication Critical patent/JP2004163388A/ja
Publication of JP2004163388A5 publication Critical patent/JP2004163388A5/ja
Pending legal-status Critical Current

Links

JP2003095679A 2002-03-29 2003-03-31 マーカーの選択 Pending JP2004163388A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36879002P 2002-03-29 2002-03-29

Publications (2)

Publication Number Publication Date
JP2004163388A JP2004163388A (ja) 2004-06-10
JP2004163388A5 true JP2004163388A5 (https=) 2006-03-16

Family

ID=27805329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003095679A Pending JP2004163388A (ja) 2002-03-29 2003-03-31 マーカーの選択

Country Status (10)

Country Link
US (2) US20030194734A1 (https=)
EP (1) EP1349104A3 (https=)
JP (1) JP2004163388A (https=)
KR (1) KR20030078803A (https=)
CN (1) CN1495272A (https=)
AR (1) AR039212A1 (https=)
AU (1) AU2003203529A1 (https=)
BR (1) BR0303080A (https=)
CA (1) CA2422309A1 (https=)
MX (1) MXPA03002865A (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2006013862A1 (ja) * 2004-08-02 2006-02-09 Banyu Pharmaceutical Co., Ltd. Cdk4阻害剤に対する薬剤感受性の予測方法
CA2589782A1 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
KR100690250B1 (ko) * 2005-01-31 2007-03-12 디지탈 지노믹스(주) 폐암 진단용 마커
JP2008528024A (ja) * 2005-01-31 2008-07-31 ディジタルジェノミクスインコーポレーション 肺癌診断用マーカー遺伝子
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
IL177006A0 (en) 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
US20070207467A1 (en) 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
CA2644586A1 (en) * 2006-03-03 2008-04-17 Veridex Llc Molecular assay to predict recurrence of duke's b colon cancer
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP1939805A1 (en) * 2006-12-22 2008-07-02 X-Shares Advisors LLC Portfolio selection for custom indices of public securities based on state of domicile of issuing company
EP2413142B1 (en) 2007-02-27 2013-06-05 Nuclea Biomarkers LLC Method for predicting the response of NSCLC-patients to treatment by an EGFR-TK inhibitor
CA2712773A1 (en) * 2008-01-22 2009-07-30 Veridex, Llc Molecular staging of stage ii and iii colon cancer and prognosis
EP2271775A4 (en) 2008-04-08 2011-09-07 Nuclea Biomarkers Llc BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
WO2010124372A1 (en) 2009-04-29 2010-11-04 Genomedx Biosciences, Inc. Systems and methods for expression-based classification of thyroid tissue
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2005927A1 (en) * 1988-12-21 1990-06-21 Chander Bahl Method of preparing nucleotide probes using a bridging complement
US6350576B1 (en) * 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
US6275814B1 (en) * 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) * 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6401043B1 (en) * 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
US6714925B1 (en) * 1999-05-01 2004-03-30 Barnhill Technologies, Llc System for identifying patterns in biological data using a distributed network
US6175824B1 (en) * 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
IL147657A0 (en) * 1999-07-15 2002-08-14 Res Dev Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof

Similar Documents

Publication Publication Date Title
BE2013C067I2 (https=)
BE2013C038I2 (https=)
BE2013C036I2 (https=)
BE2011C030I2 (https=)
BE2013C034I2 (https=)
BE2012C053I2 (https=)
AU2002327736A1 (https=)
AU2002333044A1 (https=)
AU2002249912A1 (https=)
AU2003207787A1 (https=)
AU2002254171A1 (https=)
AU2002254584A1 (https=)
AU2002255066A1 (https=)
AU2002256398A1 (https=)
AU2002310561A1 (https=)
AU2002311957A1 (https=)
AU2002316235A1 (https=)
AU2001282632A1 (https=)
AU2002318342A1 (https=)
AU2002321535A1 (https=)
AU2002322913A1 (https=)
AU2002324323A1 (https=)
AU2002327042A1 (https=)
AU2002245368A1 (https=)
AU2002329412A1 (https=)